The world has been plagued by the coronavirus for two years … The virus, which was first seen in Wuhan, China in the last days of 2019, has recently been on the agenda with its variants.
Although there has been an increase in the number of cases worldwide with Delta, which has become the dominant species, the possibility that the Mu variant may render vaccines ineffective is highlighted.
As the scientific world searched for the answer to the question “Is there a need for a new vaccine after the variants”, a lightning step came from China.
According to Sputnik news, Chinese company Sinopharm has announced that it has developed an mRNA-based vaccine against new variants of the coronavirus.
An official from China’s National Biotec Group told China Central Television in an interview that Sinopharm has already developed four vaccines, two inactivated, one mRNA vaccine and one recombinant.
“The China National Biotec Group is constantly looking for solutions to complex scientific and technical problems. Research and development of the second generation vaccine against mutated strains of Kovid-19 has yielded good results.
class = “cf”>
Stressing that the mRNA vaccine aims to combat newer variants of Kovid-19, the official said the vaccine will be released as soon as possible.
China had produced more than 2 billion doses of vaccines, most of which were inactive, developed by Sinopharm and Sinovac.
The efficacy rate of the Sinovac vaccine (two doses), also used in Turkey, has been reported at 83%.